+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Dyskinesia Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • ID: 4830049
  • Drug Pipelines
  • Region: Global
  • 121 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • A2M Pharma GmbH
  • Cadent Therapeutics
  • Clevexel Pharma SAS
  • IRLAB Therapeutics AB
  • MentiNova Inc
  • Neurolixis Inc
  • MORE
High levels of pipeline activity are being observed in Dyskinesia treatment during 2019. Clinical development activities are being undertaken by more than 30 companies including A2M Pharma GmbH, Addex Therapeutics Ltd, Amarantus Bioscience Holdings Inc, Astraea Therapeutics LLC , Avanir Pharmaceuticals Inc and others.

A Significant contribution to the Dyskinesia pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Dyskinesia pipeline included 32 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Dyskinesia condition and increased access to investments is encouraging growth of Dyskinesia drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Dyskinesia drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Dyskinesia therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Dyskinesia pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Dyskinesia. Further, orphan drug status, fast track designation, grants awarded and other special status for Dyskinesia pipeline compounds are also included.

This study was produced independently by the publisher from their proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Dyskinesia pipeline and formulate effective research and development strategies.

Research Methodology

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Dyskinesia Pipeline candidates
  • Pre-clinical Phase: Discovery, research, pre-clinical
  • Early Phase: Phase 1 and Phase 2 Dyskinesia drugs
  • Late phase: Phase 3 and in-approval Dyskinesia drugs
Companies involved in the Pipeline
  • Company overview
  • Snapshot
  • Dyskinesia therapeutic treatment activities
Details for each Dyskinesia drug candidate
  • Snapshot
  • Drug Name
  • Alternative Names
  • Company
  • Originator
  • Phase
  • Molecule Type
  • Orphan Drug Status
  • Drug Overview
  • Mechanism of Action
  • Current Status
  • Trial Details
Other details
  • Pre-clinical trials for each drug candidate
  • Clinical trials for each drug candidate
Recent Dyskinesia therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • A2M Pharma GmbH
  • Cadent Therapeutics
  • Clevexel Pharma SAS
  • IRLAB Therapeutics AB
  • MentiNova Inc
  • Neurolixis Inc
  • MORE
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Dyskinesia- Disease Overview
2.2 Dyskinesia- Pipeline Snapshot
2.3 Dyskinesia- Pipeline Drugs by Phase
2.4 Dyskinesia- Pipeline Drugs by Company
2.5 Dyskinesia- Pipeline Drugs by Mechanism of Action

3 Company wise Pipeline Analysis
3.1 A2M Pharma GmbH Dyskinesia Drug Pipeline, H2- 2019
3.2 Addex Therapeutics Ltd Dyskinesia Drug Pipeline, H2- 2019
3.3 Amarantus Bioscience Holdings Inc Dyskinesia Drug Pipeline, H2- 2019
3.4 Astraea Therapeutics LLC Dyskinesia Drug Pipeline, H2- 2019
3.5 Avanir Pharmaceuticals Inc Dyskinesia Drug Pipeline, H2- 2019
3.6 Cadent Therapeutics Dyskinesia Drug Pipeline, H2- 2019
3.7 Cavion LLC Dyskinesia Drug Pipeline, H2- 2019
3.8 Cerevance Inc Dyskinesia Drug Pipeline, H2- 2019
3.9 Clevexel Pharma SAS Dyskinesia Drug Pipeline, H2- 2019
3.10 Contera Pharma ApS Dyskinesia Drug Pipeline, H2- 2019
3.11 EpiVax Inc Dyskinesia Drug Pipeline, H2- 2019
3.12 Hua Medicine (Shanghai) Ltd Dyskinesia Drug Pipeline, H2- 2019
3.13 India Globalization Capital Inc Dyskinesia Drug Pipeline, H2- 2019
3.14 IRLAB Therapeutics AB Dyskinesia Drug Pipeline, H2- 2019
3.15 Junaxo Inc Dyskinesia Drug Pipeline, H2- 2019
3.16 Lundbeck AS Dyskinesia Drug Pipeline, H2- 2019
3.17 Melior Pharmaceuticals II LLC Dyskinesia Drug Pipeline, H2- 2019
3.18 MentiNova Inc Dyskinesia Drug Pipeline, H2- 2019
3.19 Merz Pharma GmbH & Co. KgaA Dyskinesia Drug Pipeline, H2- 2019
3.20 MitoDys Therapeutics Ltd Dyskinesia Drug Pipeline, H2- 2019
3.21 Mylan NV Dyskinesia Drug Pipeline, H2- 2019
3.22 Neurim Pharmaceuticals Ltd Dyskinesia Drug Pipeline, H2- 2019
3.23 Neurocrine Biosciences Inc Dyskinesia Drug Pipeline, H2- 2019
3.24 Neurolixis Inc Dyskinesia Drug Pipeline, H2- 2019
3.25 Newron Pharmaceuticals SpA Dyskinesia Drug Pipeline, H2- 2019
3.26 Phenomenome Discoveries Inc Dyskinesia Drug Pipeline, H2- 2019
3.27 PolyCore Therapeutics LLC Dyskinesia Drug Pipeline, H2- 2019
3.28 Revance Therapeutics Inc Dyskinesia Drug Pipeline, H2- 2019
3.29 Sage Therapeutics Inc Dyskinesia Drug Pipeline, H2- 2019
3.30 SalubRx Therapeutics Inc Dyskinesia Drug Pipeline, H2- 2019
3.31 SOM Biotech SL Dyskinesia Drug Pipeline, H2- 2019
3.32 Ultragenyx Pharmaceutical Inc Dyskinesia Drug Pipeline, H2- 2019

4 Phase 1 Pipeline Drug Details
4.1 Dyskinesia- Phase 1 Drug Details
4.2 Dyskinesia- Phase 1 Drug Overview
4.3 Dyskinesia- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 Phase 2 Pipeline Drug Details
5.1 Dyskinesia- Phase 2 Drug Details
5.2 Dyskinesia- Phase 2 Drug Overview
5.3 Dyskinesia- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 Phase 3 Pipeline Drug Details
6.1 Dyskinesia- Phase 3 Drug Details
6.2 Dyskinesia- Phase 3 Drug Overview
6.3 Dyskinesia- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 Pre-clinical Phase Pipeline Drug Details
7.1 Dyskinesia- Pre-clinical Phase Drug Details
7.2 Dyskinesia- Pre-clinical Phase Drug Overview
7.3 Dyskinesia- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 Recent News and Developments

9 Appendix
9.1 About the Publisher
9.2 Sources and Research Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • A2M Pharma GmbH
  • Addex Therapeutics Ltd
  • Amarantus Bioscience Holdings Inc
  • Astraea Therapeutics LLC
  • Avanir Pharmaceuticals Inc
  • Cadent Therapeutics
  • Cavion LLC
  • Cerevance Inc
  • Clevexel Pharma SAS
  • Contera Pharma ApS
  • EpiVax Inc
  • Hua Medicine (Shanghai) Ltd
  • India Globalization Capital Inc
  • IRLAB Therapeutics AB
  • Junaxo Inc
  • Lundbeck AS
  • Melior Pharmaceuticals II LLC
  • MentiNova Inc
  • Merz Pharma GmbH & Co. KgaA
  • MitoDys Therapeutics Ltd
  • Mylan NV
  • Neurim Pharmaceuticals Ltd
  • Neurocrine Biosciences Inc
  • Neurolixis Inc
  • Newron Pharmaceuticals SpA
  • Phenomenome Discoveries Inc
  • PolyCore Therapeutics LLC
  • Revance Therapeutics Inc
  • Sage Therapeutics Inc
  • SalubRx Therapeutics Inc
  • SOM Biotech SL
  • Ultragenyx Pharmaceutical Inc
Note: Product cover images may vary from those shown
Adroll
adroll